Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu

Myeloablative Conditioning, Prophylactic Defibrotide and Haplo AlloSCT for Patients With Sickle Cell Disease (NYMC-571)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02675959
Recruitment Status : Recruiting
First Posted : February 5, 2016
Last Update Posted : September 30, 2019
University of California, Los Angeles
Medical College of Wisconsin
University of Chicago
Tufts Medical Center
Baylor College of Medicine
Johns Hopkins University
Dana-Farber Cancer Institute
Information provided by (Responsible Party):
Mitchell Cairo, New York Medical College

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : December 2021
Estimated Study Completion Date : December 2022